NYSE:RDY

Dr. Reddy's Laboratories (RDY) Stock Price, News & Analysis

Dr. Reddy's Laboratories logo
$14.98 +0.19 (+1.30%)
Closing price 11/18/2026 03:59 PM Eastern
Extended Trading
$14.94 -0.04 (-0.26%)
As of 08:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Dr. Reddy's Laboratories Stock (NYSE:RDY)

Advanced

Key Stats

Today's Range
$14.76
▼
$15.05
50-Day Range
$11.54
▼
$15.03
52-Week Range
$11.36
▼
$15.67
Volume
1.79 million shs
Average Volume
2.80 million shs
Market Capitalization
$12.51 billion
P/E Ratio
40.49
Dividend Yield
0.40%
Price Target
$492.90
Consensus Rating
Hold

Company Overview

Dr. Reddy’s Laboratories is an India-based pharmaceutical company that develops, manufactures and markets generic medicines, active pharmaceutical ingredients (APIs) and other healthcare products. Its portfolio includes branded and unbranded generics, biosimilars and select proprietary medicines across therapeutic areas such as oncology, gastroenterology, cardiovascular care and diabetes.

Founded in 1984 by Kallam Anji Reddy, the company is headquartered in Hyderabad, India. It serves patients and customers in India and international markets, including the United States, Europe and countries in Russia and the Commonwealth of Independent States.

Dr. Reddy’s combines pharmaceutical research and development with manufacturing and commercialization. Its activities include developing generic versions of medicines, producing APIs for its own products and other pharmaceutical companies, and expanding access to treatments in both regulated and emerging markets.

AI Generated. May Contain Errors.

Dr. Reddy's Laboratories Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
67th Percentile Overall Score

RDY MarketRank™: 
3.340871710525 of 5 stars

Dr. Reddy's Laboratories scored higher than 67% of companies evaluated by MarketBeat, and ranked 491st out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Dr. Reddy's Laboratories has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on no strong buy ratings, 2 buy ratings, 3 hold ratings, and 1 sell rating.

  • Upside Potential

    Dr. Reddy's Laboratories has a consensus price target of $492.90, representing about 3,189.7% upside from its current price of $14.98.

  • Amount of Analyst Coverage

    Dr. Reddy's Laboratories has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Dr. Reddy's Laboratories' stock forecast and price target.
  • Earnings Growth

    Earnings for Dr. Reddy's Laboratories are expected to grow by 28.26% in the coming year, from $0.46 to $0.59 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Dr. Reddy's Laboratories is 40.49, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.91.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Dr. Reddy's Laboratories is 40.49, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 32.48.

  • Price to Earnings Growth Ratio

    Dr. Reddy's Laboratories has a PEG Ratio of 3.06. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Dr. Reddy's Laboratories has a P/B Ratio of 3.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Dr. Reddy's Laboratories' valuation and earnings.
  • Percentage of Shares Shorted

    3.09% of the float of Dr. Reddy's Laboratories has been sold short.
  • Short Interest Ratio / Days to Cover

    Dr. Reddy's Laboratories has a short interest ratio ("days to cover") of 7.81.
  • Change versus previous month

    Short interest in Dr. Reddy's Laboratories has recently decreased by 3.23%, indicating that investor sentiment is improving.
  • Dividend Yield

    Dr. Reddy's Laboratories has a dividend yield of 0.43%, which is in the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Dr. Reddy's Laboratories does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Dr. Reddy's Laboratories is 16.22%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Dividend Sustainability

    Based on earnings estimates, Dr. Reddy's Laboratories will have a dividend payout ratio of 10.17% next year. This indicates that Dr. Reddy's Laboratories will be able to sustain or increase its dividend.

  • Read more about Dr. Reddy's Laboratories' dividend.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Dr. Reddy's Laboratories this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Dr. Reddy's Laboratories insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    2.00% of the stock of Dr. Reddy's Laboratories is held by insiders.

  • Percentage Held by Institutions

    3.85% of the stock of Dr. Reddy's Laboratories is held by institutions.

  • Read more about Dr. Reddy's Laboratories' insider trading history.
Receive RDY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dr. Reddy's Laboratories and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RDY Stock News Headlines

Analyzing Dr. Reddy's Laboratories (RDY) and Its Competitors
Dr Reddy's Laboratories (RDY) AI Stock Analysis
I'm handing you this stock today
Elon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.tc pixel
Zacks Research Has Positive Outlook for RDY FY2027 Earnings
See More Headlines

RDY Stock Analysis - Frequently Asked Questions

Dr. Reddy's Laboratories' stock was trading at $14.03 at the beginning of the year. Since then, RDY stock has increased by 6.8% and is now trading at $14.9830.

Dr. Reddy's Laboratories Ltd (NYSE:RDY) posted its quarterly earnings data on Saturday, October, 24th. The company reported $0.12 earnings per share for the quarter, topping analysts' consensus estimates of $0.10 by $0.02. The company earned $903.89 million during the quarter, compared to the consensus estimate of $894.94 million. Dr. Reddy's Laboratories had a trailing twelve-month return on equity of 7.91% and a net margin of 8.56%.
Read the conference call transcript
.

Dr. Reddy's Laboratories's stock split on the morning of Tuesday, November 5th 2024.The 5-1 split was announced on Thursday, September 12th 2024. The newly issued shares were issued to shareholders after the market closes on Monday, November 4th 2024. An investor that had 100 shares of stock prior to the split would have 500 shares after the split.

Top institutional investors of Dr. Reddy's Laboratories include Aikya Investment Management Ltd (1.09%), Robeco Institutional Asset Management B.V. (1.04%), State Street Corp (0.45%) and Goldman Sachs Group Inc. (0.20%).

Shares of RDY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Dr. Reddy's Laboratories investors own include Infosys (INFY), Johnson & Johnson (JNJ), Tata Motors (TTM), Walt Disney (DIS), ICICI Bank (IBN), Qualcomm (QCOM) and Wipro (WIT).

Company Calendar

Last Earnings
10/24/2026
Today
11/19/2026
Next Earnings (Estimated)
1/22/2027
Fiscal Year End
3/31/2027

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NYSE:RDY
CIK
1135951
Employees
27,527
Year Founded
1984

Price Target and Rating

High Price Target
$1,450.00
Low Price Target
$13.90
Potential Upside/Downside
+3,189.7%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
6 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.37
Trailing P/E Ratio
40.49
Forward P/E Ratio
25.39
P/E Growth
3.06
Net Income
$456 million
Net Margins
8.56%
Pretax Margin
9.54%
Return on Equity
7.91%
Return on Assets
5.29%

Debt

Debt-to-Equity Ratio
0.03
Current Ratio
1.93
Quick Ratio
1.40

Sales & Book Value

Annual Sales
$329.84 billion
Price / Sales
0.04
Cash Flow
$0.86 per share
Price / Cash Flow
17.46
Book Value
$4.86 per share
Price / Book
3.08

Miscellaneous

Outstanding Shares
835,262,000
Free Float
818,557,000
Market Cap
$12.51 billion
Optionable
Optionable
Beta
0.31

Social Links

The 7 Hottest IPO Stories of 2026 Cover

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

This page (NYSE:RDY) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners